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Transplantation Outcome in Patients with
Myelodysplastic Syndrome but Not in Those
with Chronic Myelogenous Leukemia, Independent
of the Presence of HLA-DR15
Laura F. Newell,1,2 Ted Gooley,1,3 John A. Hansen,1,2 Derek L. Stirewalt,1,2
Effie W. Petersdorf,1,2 H. Joachim Deeg1,2Both the presence of HLA-DR15 and tumor necrosis factor (TNF)-a levels have been reported to affect
outcome after hematopoietic cell transplantation (HCT). Patients with a myelodysplastic syndrome
(MDS) show a high prevalence of HLA-DR15 and express high levels of TNF-a in the bone marrow. The
present analysis involving 7950 patients showed an HLA-DR15 frequency of 31% in patients with MDS, com-
pared with only 23% in patients with chronic myelogenous leukemia (CML). HLA-DR15 was more prevalent
in Caucasian patients than in non-Caucasian patients (P5.01). The numbers of patients in the non-Caucasian
subgroups were too small to allow further analysis. Among Caucasian patients with MDS and CML, the
presence of HLA-DR15 did not significantly affect the occurrence of graft-versus-host disease, relapse,
nonrelapse mortality (NRM), or survival. However, there was a significant correlation between DR15 and
TNF polymorphisms at position -308 among patients with MDS, and the TNF-308 AG genotype conferred
an increased risk of NRM compared with the GG genotype (hazard ratio [HR], 1.49; P 5 .02), even after
adjusting for DR15. Conversely, the TNF-863 AA genotype was correlated with decreased overall mortality
and NRM compared with the CC genotype (HR, 0.36, P5 .04 vs HR, 0.13, P5 .04), even after adjusting for
DR15. There was no significant association between TNF-308 or -863 polymorphisms and transplantation
outcome in CML patients. These results suggest that TNF polymorphisms, but not DR15, affect transplan-
tation outcome in a disease-dependent manner.
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Major histocompatibility complex (MHC) class II
genes (HLA-DR, -DQ, and -DP in humans) were orig-
inally described in themouse as immune response genes
[1]. Subsequently, many examples of disease association
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6/j.bbmt.2010.06.003recognized. In the setting of hematopoietic cell trans-
plantation (HCT), the presence of the class II antigen
HLA-DR2 (subsequently split into DR15 and DR16)
was reported to affect transplantation outcome, particu-
larly the occurrence of graft-versus-host disease
(GVHD) and survival [2-4]. Centromeric to the HLA
gene complex on chromosome 6, and closely linked to
HLA-DR, is the gene encoding the proinflammatory
cytokine tumor necrosis factor (TNF)-a, which is also
thought to play a role in transplantation outcome
[5,6]. As we and others have shown, significant up-
regulationofTNFin themarrowofpatientswith amye-
lodysplastic syndrome (MDS) and HLA-DR15 (DR2)
have been associated with MDS [7-10]. We were
interested in investigating whether transplantation
outcome in patients with MDS is dependent on the
presence of HLA-DR15, TNF genotype, or both.
TNF shows single nucleotide polymorphisms
(SNPs) at positions -308 and -863. The TNF-308
Biol Blood Marrow Transplant 16:1700-1706, 2010 1701TNF Polymorphism and Transplant Outcome in MDSposition consists of a guanine (G) or an adenine nucle-
otide (A). The TNF-308 GG genotype has been
shown to result in higher TNF levels compared with
the AA genotype [11]. Kroeger et al. [12] reported
that the -308 polymorphism altered the affinity of
nuclear factor binding and differentially affected
transcription of the TNF-a gene; the presence of an
adenine nucleotide at -308 increased transcription at
least 2-fold above the levels seen with guanine. The
TNF-863 cytosin (C) and adenine (A) polymorphism,
which has been implicated in several autoimmune
diseases [13,14], has been speculated to influence
TNF-a expression through differential binding of
nuclear factor-kB (NF-kB) complexes and through
allele-specific chromatin remodeling [15]. The -863
A allele ultimately is associated with increased
TNF-a production [16].
In the present study, we first analyzed the preva-
lence of HLA-DR15 in 7950 patients who underwent
HCT for various hematologic disorders, including
MDS. Our findings confirmed a high prevalence in
patients with MDS. We then selected the cohort of
patients with the lowest prevalence of HLA-DR15,
those with chronic myelogenous leukemia (CML), as
a comparison group. We used these two cohorts to
evaluate linkage disequilibrium between HLA-DR15
and the TNF-308 and -863 SNPs in our patient pop-
ulation, and also to analyze the effects of HLA-DR15
alleles and TNF polymorphisms on transplantation
outcome.METHODS
Patient, Disease, and Transplant Characteristics
This retrospective analysis involved 7950 patients
undergoing a firstHCTat the FredHutchinsonCancer
Research Center for aplastic anemia, acute myeloge-
nous and lymphoblastic leukemias, chronic lympho-
cytic leukemia, CML, Hodgkin disease, multiple
myeloma, non-Hodgkin lymphoma, or MDS. Details
of the conditioning regimens; GVHD diagnosis, pro-
phylaxis, and therapy; infection prophylaxis; supportive
care measures; and assessment of relapse have been
reported elsewhere [17-22]. All patients provided
informed consent for ongoing research studies in
accordance with the requirements of Fred Hutchinson
Cancer Research Center’s Institutional Review Board.HLATyping
Related donors were HLA-identical siblings or mis-
matched relatives as determined by family study before
HCT [23]. Unrelated donors were characterized for
HLA-A, -B, -C, -DRB1, and -DQB1 alleles using
sequence-specific oligonucleotide probe hybridization
or sequencing methods [23]. Patients who expressed atleast one copy of a DR15 allele were classified as
DR15-positive.
Genotyping of TNF SNPs
Genotyping of the SNPs of TNF-a involving po-
sitions -308 and -863 was carried out by a multiplex
polymerase chain reaction (PCR) assay, as described
previously [24]. No TNF typing was done besides
that performed for a previous study [24].
Statistical Analysis
The c2 test was used to compare the frequency of
DR15across various diagnoses, aswell as the association
between the presence of DR15 and the TNF genotype.
Cox regression was used to examine the association be-
tween both the presence of DR15 and TNF genotype
and the time-to-event outcomes overall mortality,
relapse, and nonrelapse mortality (NRM). Logistic
regression was used to examine the same associations
with the outcome of grade II-IV acute GVHD
(aGVHD). Regressionmodels were adjusted for patient
age, disease severity (high vs low), and type of donor
(HLA-identical sibling vs others).Given the linkage dis-
equilibrium between DR15 and TNF, both DR15 and
each of the TNF polymorphisms were included in all
regression models, to evaluate the association of one
after adjustment for the others. Two-sided P values
from regression models were estimated from the Wald
test; no adjustments were made for multiple compari-
sons [25].RESULTS
Frequencies of HLA-DR15 and TNF
Polymorphisms Depend on Diagnosis and Racial
Origin
A total of 6866 Caucasian and 1084 known non-
Caucasian patients undergoing firstHCT at our center
had HLA data available that allowed categorization in
terms of expressing or not expressing at least one copy
of a DR15 allele. The frequency of DR15 was higher in
Caucasians than in non-Caucasians (25.8% vs 22.3%;
P5 .01). Among 765Caucasian patients with a diagno-
sis of MDS, 237 (31.0%) had at least one DR15 allele,
compared with 393 of 1644 patients with CML
(23.9%). The frequencies of other diagnoses are listed
in Table 1. A global test of the equality of the propor-
tion of patients positive for DR15 across all diseases
yielded P 5 .001, supporting the hypothesis that the
prevalence of DR15 differs significantly depending
on the diagnosis. Characteristics of the patients with
MDS or CML are summarized in Table 2.
The frequency of the TNF-308 genotypes differed
between Caucasians and non-Caucasians. Specifically,
the GG genotype occurred in 68.5% of Caucasians
Table 1. Incidence of the DRB15** Allele by Disease Cate-
gory in Caucasian Patients
Disease
Number of Patients
with $ 1 Copy
of a DRB15**
Allele/Total Number
Percent DRB
15-Positive
Aplastic anemia 84/325 25.8
ALL 237/993 23.9
Acute myelogenous leukemia 481/1907 25.2
Chronic lymphocytic leukemia 28/97 28.9
CML 393/1644 23.9
Hodgkin disease 57/162 35.2
Multiple myeloma 98/343 28.6
Non-Hodgkin lymphoma 158/630 25.1
MDS 237/765 31.0
ALL indicates acute lymphoblastic leukemia; CML, chronic myelogenous
leukemia; MDS, myelodysplastic syndrome.
Table 3. Allele and Genotype Frequencies of TNF-308 and
-863 SNPs and Association between HLA-DR15 and TNF
SNPs in Caucasian Patients with MDS or CML
MDS CML
c2 P Values
for MDS
and CML
TNF-308 alleles*
A 120/375 (32%) 181/593 (30.5%)
G 366/375 (97.6%) 577/593 (97.3%)
Genotypes
AA 9/375 (2.4%) 16/593 (2.7%)
AG 111/375 (29.6%) 165/593 (27.8%)
GG 255/375 (68%) 412/593 (69.5%)
TNF-863 alleles*
A 115/372 (30.7%) 165/593 (27.8%)
C 358/372 (95.5%) 582/593 (98.1%)
Genotypes
AA 14/372 (3.8%) 11/593 (1.9%)
AC 101/372 (27.2%) 154/593 (26.0%)
CC 257/372 (69.1%) 428/593 (72.2%)
Proportion of DR15-positive patients
TNF-308 P 5 .003, P 5 .54
AA 0/9 2/16 (12.5%)
AG 26/111 (23.4%) 37/165 (22.4%)
GG 97/255 (38.0%) 99/412 (24.0%)
TNF-863 P 5 .11, P 5 .03
AA 5/14 (35.7%) 0/11
AC 25/101 (24.8%) 28/154 (18.2%)
CC 93/257 (36.2%) 110/428 (25.7%)
SNP indicates single nucleotide polymorphism; ALL, acute lymphoblastic
leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic
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present in 29.2% of Caucasians and in 13.0% of
non-Caucasians, and the AA genotype was present in
2.6% of Caucasians and in 1.1% of non-Caucasians
(P \ .0001). The differences in frequency of the
TNF-863 genotypes were not as marked, but were still
statistically significant (P5 .02). Based on these differ-
ences, we restricted the subsequent analyses to the
Caucasian population. Table 3 summarizes the allele
and genotype frequencies for the TNF-308 and -863Table 2. Patient, Disease, and Transplant Characteristics of
Caucasian Patients with MDS or CML
MDS CML
Number of patients 765 1644
Age, years, median (range) 48.3 (0.9-78.9) 37.1 (0.7-69.7)
Patient-donor sex match, n (%)
Female-female 150 (20) 307 (19)
Female-male 168 (22) 343 (21)
Male-female 186 (24) 401 (24)
Male-male 253 (33) 588 (36)
Unknown 8 (1) 5 (<1)
Conditioning regimen, n (%)*
High intensity 706 (92) 1626 (99)
Reduced intensity 59 (8) 18 (1)
Donor, n (%)
HLA-identical sibling 346 (45) 731 (44)
HLA-matched unrelated donor 349 (46) 676 (41)
Nonsibling relative or
mismatched sibling
62 (8) 235 (14)
Autologous† 8 (1) 2 (<1)
Stem cell source, n (%)
Bone marrow 403 (53) 1522 (93)
Peripheral blood 356 (47) 117 (7)
Bone marrow and peripheral blood 4 (<1) 2 (<1)
Umbilical cord blood 2 (<1) 3 (<1)
Period of transplantation, n (%)
1969-1985 26 (3) 228 (14)
1986-1990 75 (10) 391 (24)
1991-1995 162 (21) 490 (30)
1996-2000 173 (23) 393 (24)
2001-2005 224 (29) 113 (7)
2006-present 105 (14) 29 (2)
MDS indicates myelodysplastic syndrome; CML, chronic myelogenous
leukemia.
*High intensity: cyclophosphamide (Cy)/total body irradiation (TBI),
busulfan (B)/Cy, and fludarabine (Flu)/Bu [31-34]; reduced intensity:
Flu/TBI [35].
†Not considered further in the outcome analysis.
syndrome.
*Heterozygotes contribute to both allele categories.SNPs in Caucasians, along with the correlation with
DR15, which was significant for TNF-308 (P 5 .003).
The number of patients in any particular non-Caucasian
population was not sufficiently large to allow separate
analyses.
DR15 and TNF-308 and -863 Polymorphisms in
MDS and CML
Table 3 summarizes the associations between SNP
genotypes and DR15. The frequency of DR15 differed
across TNF-308 genotypes in patients with MDS
(P5 .003), and the presence of at least one DR15 allele
was suggestively (but not statistically significantly)
different across TNF-863 genotypes (P 5 .11). In
patients with CML, the presence of DR15 was not
statistically significantly correlated with the TNF-
308 genotype (P 5 .54), whereas it was correlated
with the TNF-863 genotype (P 5 .03).
Associations of DR15 Positivity and TNF-308
and -863 SNPs with TransplantationOutcome in
MDS Patients
After adjusting for TNF-863 and the presence of
DR15, the TNF-308 AG genotype in patients with
MDS was associated with an increased risk of NRM
relative to the GG genotype. Overall mortality was
also increased, but not significantly so (Table 4). The
AA genotype also tended to be associated with
increased failure rate relative to the GG genotype for
Table 4. Association of DR15 and TNF-308 and -863 SNPs with Transplantation Outcome in Caucasian Patients with MDS
Determinant Overall Mortality Relapse NRM aGVHD Grade II-IV
TNF-308
GG 1 1 1 1
AG 1.20 (0.90-1.62); P 5 .21 0.76 (0.43-1.35); P 5 .35 1.41 (1.01-1.98); P 5 .05 1.46 (0.82-2.59); P 5 .21
AA 1.57 (0.72-3.42); P 5 .26 1.99 (0.59-6.70); P 5 .27 1.21 (0.44-3.37); P 5 .71 0.69 (0.15-3.14); P 5 .47
TNF-863
CC 1 1 1 1
AC 1.19 (0.88-1.61); P 5 .26 1.74 (1.05-2.87); P 5 .03 1.12 (0.78-1.60); P 5 .55 0.79 (0.45-1.37); P 5 .97
AA 0.39 (0.14-1.06); P 5 .06 1.24 (0.44-3.52); P 5 .69 0.15 (0.02-1.05); P 5 .06 0.64 (0.19-2.09); P 5 .58
DR15
Absent 1 1 1 1
Present 1.03 (0.77-1.38); P 5 .84 0.89 (0.53-1.49); P 5 .66 1.00 (0.71-1.42); P 5 .99 1.29 (0.76-2.21); P 5 .35
SNP indicates single nucleotide polymorphism. Values listed are HR and 95% CI for overall mortality, relapse, and NRM and OR and 95% CI for GVHD.
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associations was statistically significant (Table 4),
because there were only 9 patients with this genotype.
No statistically significant association was found be-
tween TNF-308 SNPs and relapse (Table 4). Patients
with the TNF-863 AC genotype had similar overall
mortality and NRM as those with the CC genotype
(Table 4), whereas patients with the AA genotype had
lower overall mortality and NRM compared with those
with the CC genotype. The small number of patients
with the AA genotype (n5 14) mandates a cautious in-
terpretation of these results, however. The associations
between TNF and overall mortality, NRM, and relapse
did not appear to depend on the presence of DR15
(with interaction P values ranging from .39 to .95).
Moreover, the magnitudes of the associations between
TNF and each of these outcomes after adjusting for
the presence of DR15 were virtually the same as the
magnitudes of associations between TNF and out-
comes without adjusting for the presence of DR15.
No statistically significant association was found
between TNF-863 SNPs and aGVHD (Table 4).
The impact of the presence of TNF-308 SNPs on
grade II-IV aGVHD was dependent on DR15 status
(P 5 .04, test of interaction). In DR15-negative pa-
tients, the TNF-308 AG genotype was associated
with an increased risk of aGVHD compared to pa-
tients with the GG genotype (odds ratio [OR], 2.25;
95% confidence interval [CI], 1.12-4.49; P 5 .02);
however, the association of the TNF-308 AG geno-
type with aGVHD in DR15-positive patients was in
the opposite direction (OR, 0.37; 95% CI, 0.12-1.11;
P5 .08). Furthermore, no statistically significant asso-
ciation was noted between the presence of an HLA-
DR15 allele per se and transplantation outcome (i.e.,
overall mortality, relapse, NRM, or grade II-IV
aGVHD) (Table 4).Association of DR15 Positivity and TNF-308 and
-863 SNPs with Outcome in CML Patients
Among CML patients, no statistically significant
associations were found among TNF-308 or -863
SNPs and overall mortality, relapse, NRM, and gradeII-IV aGVHD. In addition, there was no statistically
significant association between the presence of
a DR15 allele and outcome (Table 5).
HLA-B, TNF Polymorphisms, and
Transplantation Outcome
Given the location of the TNF gene within 200 kb
of HLA-B, we also evaluated possible associations
between HLA-B and TNF. Several HLA-B antigens
showed an association with the TNF SNPs examined,
but none of the associations between TNF and trans-
plantation outcome was qualitatively changed after
adjustments were made for the presence of these
HLA-B antigens (data not shown).DISCUSSION
The present analysis of data from patients under-
going HCT for lymphoid or hematologic disorders
shows significant disease-dependent differences in
the frequency of the presence of HLA-DR15, with at
least one DR15 allele found in 31% of patients with
MDS and 23% of those with CML. A second analysis,
restricted toCaucasian patients withMDS orCML for
whommolecular information onTNF polymorphisms
was available, showed a statistically significant correla-
tion of the TNF-308 genotype with DR15 in MDS
patients, but not in CML patients. The TNF-863
genotype showed a suggestive correlation with DR15
in MDS patients and a statistically significant correla-
tion in CML patients. In patients with MDS, the
TNF-308 AG genotype was associated with an in-
creased risk of NRM relative to the GG genotype,
whereas, conversely, the -863 AA genotype was associ-
ated with a suggestively decreased risk of overall
mortality and NRM relative to the CC genotype.
These results must be interpreted with caution, how-
ever, because of the small number of patients with
the TNF-863 AA genotype. Importantly, these associ-
ations were seen after adjusting for the presence of
DR15 alleles, suggesting that the presence or absence
of DR15 did not explain the association of the TNF
SNPs with transplantation outcome. In contrast to
Table 5. Lack of Association of DR15 and TNF-308 and -863 SNPs with Outcome in Caucasian Patients with CML
Determinant Overall Mortality Relapse NRM aGVHD Grade II-IV
TNF-308
GG 1 1 1 1
AG 0.97 (0.74-1.28); P 5 .85 1.31 (0.89-1.91); P 5 .17 0.99 (0.71-1.36); P 5 .93 0.82 (0.51-1.33); P 5 .43
AA 0.85 (0.40-1.83); P 5 .68 0.85 (0.27-2.74); P 5 .79 0.82 (0.33-2.01); P 5 .82 0.86 (0.24-3.05); P 5 .81
TNF-863
CC 1 1 1 1
AC 1.06 (0.81-1.40); P 5 .67 1.32 (0.90-1.94); P 5 .16 0.97 (0.70-1.36); P 5 .87 0.86 (0.53-1.41); P 5 .56
AA 1.14 (0.53-2.45); P 5 .74 0.89 (0.21-3.66); P 5 .87 1.06 (0.43-2.65); P 5 .89 0.52 (0.12-2.32); P 5 .39
DR15
Absent 1 1 1 1
Present 0.92 (0.68-1.23); P 5 .55 0.98 (0.65-1.48); P 5 .91 0.92 (0.65-1.31); P 5 .65 1.14 (0.68-1.89); P 5 .63
Values listed are HR (95% CI) for overall mortality, relapse, and NRM and OR (95% CI) for GVHD.
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statistically significant effects of TNF-308 and -863
SNPs on transplantation outcome. Neither the MDS
nor the CML cohort demonstrated any statistically
significant associations between DR15 itself and trans-
plantation outcome.
Our results are in contrast to those in some previous
reports that showed correlations between DR15 and
transplantation outcome in patients with various diag-
noses [2-4]. For example, Stern et al. [4] observed a sig-
nificantly higher 5-year survival rate in DR15-positive
patients compared with DR15-negative patients (76%
vs 55%; P5 .04), along with a lower 5-year probability
of disease-related mortality in the DR15-positive
patients (5% vs 24%; P 5 .02). Similar data were
reportedbyBattiwallaet al. [2],who foundasignificantly
lower incidence of aGVHD in DR15-positive patients
than inDR15-negativepatients (23%vs42%;P5 .041).
However, that analysis included only 20 patients with
MDS, and patients with serologically determined DR2
(who had not been allele-typed) were included in the
DR15-negative group. In the study by Davidson et al.
[3], DR15-positive adult patients demonstrated im-
proved day 100 survival (P 5 .03) and overall survival
(P 5 .0143). Moreover, in patients who developed
aGVHD, survival was superior in those who were
DR15-positive (P5 .02).However, an analysis of results
in 88 patients undergoing HCT from HLA-identical
unrelated donors showed inferior survival with DR15
positivity (P5 .02), andDR15-negativitywas associated
with improved survival in patients who developed
aGVHD (P5 .009).
In the present study, we found no correlation be-
tween the presence or absence of HLA-DR15 and
transplantation outcomes, including GVHD, relapse,
NRM, and survival. Although it is conceivable that
differences in results among reports are related to
differing compositions of the patient cohorts studied,
we found no correlation of DR15 with outcome in
patients with either MDS or CML undergoing trans-
plantation from either related or unrelated donors.
Similarly, we noted no associations between specific
HLA-B alleles and transplantation outcome. In fact,our data suggest correlations with TNF polymor-
phisms, particularly the TNF–308 G allele. Of course,
although 91% of the patients with MDS and 85% of
those with CML had an HLA-matched donor (includ-
ing HLA-DR), TNF polymorphism data were
obtained only from patients, and these data might
have differed from those for the donors, particularly
in the unrelated donor setting.
Lin et al. [24] analyzed data from 570 patients who
underwentHCT at our center and their HLA-identical
sibling donors for an association between GVHD and
cytokine SNPs [24]. They analyzed 7 different SNPs
in 5 cytokine genes, including TNF-308, and found
no statistically significant association between
aGVHD and the TNF-308 genotype. That study in-
cluded patients with various diagnoses, however, and
in view of the differences among different diagnostic
groups observed in the present analysis, the data cannot
be globally extrapolated. Middleton et al. [26] deter-
mined TNF and interleukin-10 polymorphic allele
frequencies in 80 patients with ALL or CML. They
then correlated the polymorphism results with the inci-
dence and severity of GVHD in 49 patients who subse-
quently underwent HCT from an HLA-identical
sibling donor. They found no significant association
of outcome with the TNF-308 polymorphism,
although they did observe an association of GVHD
with a microsatellite near the TNF locus. Takahashi
et al. [27] reported a significant association between
the donor TNF-308 SNP (which was not determined
in the present study) and the severity of aGVHD
(P 5 .04) in patients undergoing transplantation pri-
marily from HLA-identical related donors. Although
patient TNF-308 polymorphism pretransplantation
was not associated with aGVHD, there was a significant
association with polymorphism in postengraftment
samples (P 5 .04), suggesting a relationship to donor
cell polymorphism. In yet another analysis of results
in 77 patients undergoing transplantation from HLA-
identical sibling donors, Bertinetto et al. [28] observed
significant associations between grade II-IV GVHD
and TNF-308 or -863 polymorphisms. Finally, Shaw
et al. [29] reported delayed neutrophil engraftment in
Biol Blood Marrow Transplant 16:1700-1706, 2010 1705TNF Polymorphism and Transplant Outcome in MDSpatients with CML, acute leukemia, or other malignant
disease undergoing transplantation from a related or an
unrelated donor if the TNF-308 AG genotype was
present in either the patient (P 5 .03) or the donor
(P5 .02). No such correlation was found in the present
study (data not shown).
Although both TNF-308 and -863 SNPs are
thought to be associated with increased levels of
TNF-a production, the present analysis showed quite
different effects on post-HCT outcomes in MDS
patients. Patients with the -308 AG genotype had an
increased risk of NRM relative to those with the GG
genotype, whereas patients with the -863 AA genotype
had suggestively decreased risks of overall mortality and
NRM relative to the CC genotype. Of course, our anal-
ysis, much like other reports, did not include the study
ofTNF-a protein levels in either blood ormarrow [30],
which would be desirable tomore firmly establish a role
of the gene product in transplantation outcome.
As far as a potential impact of HLA-DR15 on treat-
ment outcome is concerned, several hypotheses have
been proposed. It has been suggested that the molecule
preferentially presents autoantigens on hematopoietic
precursor cells, thereby evoking an immune reaction
of T cells [4,7]. It also has been suggested that DR15
is associated with an immune profile that increases the
responsiveness to immunosuppressive therapy [2]. In
view of the present results, which suggest that trans-
plantation outcome was affected primarily by TNF
polymorphisms (in linkage disequilibrium with HLA-
DR alleles) rather than byDR alleles themselves, focus-
ing future studies on cytokine profiles [24,26,27] might
prove more productive.
In summary, in the present study we found signifi-
cant differences in the frequency of HLA-DR15 in
patients with different hematologic diagnoses who
were referred for HCT. The data in Caucasian patients
showed anassociationofDR15withTNF-308 and -863
polymorphisms and an effect of these polymorphisms
on transplantation outcome in patients with MDS, but
not in a large comparison group of patients with
CML. The data suggest that previously reported corre-
lations of transplant outcome with DR15 might in fact
be correlations with TNF polymorphisms. As ongoing
clinical studies are exploring the effect ofTNFblockade
on transplantation outcomes, examiningwhether thera-
peutic results are correlated with TNF genotype might
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